Review

Nature Reviews Drug Discovery 2, 973-985 (December 2003) | doi:10.1038/nrd1251

GLIA: A novel drug discovery target for clinical pain

Linda R. Watkins1 & Steven F. Maier1  About the authors

Top

In many clinical pain syndromes, painful sensations are greatly amplified so that normally innocuous sensations, such as light touch or warmth, are perceived as pain. Presently available drugs are ineffective in controlling such pain in most patients and abolish the pain in only few. Why do they fail? These drugs were developed to target neurons that transmit nociceptive ('pain') information. However, glia have recently been recognized as powerful modulators of nociception, and could hold the key to the control of clinical pain and present a new target for drug discovery. This review examines the evidence for glial regulation of nociception and pharmacological approaches that might successfully control glially driven clinical pain syndromes.

Author affiliations

  1. Department of Psychology and the Center for Neuroscience, University of Colorado at Boulder, Boulder, Colorado 80309-0345, USA.

Correspondence to: Linda R. Watkins1 Email: lwatkins@psych.colorado.edu.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REFERENCE
Substance P
Nature Encyclopaedia of Life Sciences
Somatosensory Systems
Nature Encyclopaedia of Life Sciences
See all 5 matches for Reference

NEWS AND VIEWS
Sensory neurons are PARtial to pain
Nature Medicine News and Views (01 Jul 2001)
Breaking the pain barrier
Nature Medicine News and Views (01 Nov 2003)
See all 8 matches for News And Views

RESEARCH
Attenuation of Morphine Tolerance, Withdrawal-Induced Hyperalgesia, and Associated Spinal Inflammatory Immune Responses by Propentofylline in Rats
Neuropsychopharmacology Original Article (01 Feb 2004)
See all 23 matches for Research

Extra navigation

Search PubMed for

Open Innovation Challenges

natureproducts


Advertisement